Tiziana Life Sciences is expanding its Phase 2 clinical trial testing foralumab nasal spray for the treatment of nonactive secondary progressive multiple sclerosis (SPMS), with six additional clinical sites across the northeastern region of the U.S.
The new sites, all at top U.S. institutions, bring together leaders in medical research and neurology with access to innovative facilities, Tiziana stated in a company press release. The new sites are Yale University in Connecticut, Johns Hopkins University in Maryland, Cornell University and the University at Buffalo, both in New York, University of Massachusetts, and Thomas Jefferson University in Pennsylvania.
“We are honored to collaborate with these prestigious institutions as we further expand our clinical trial,” said Ivor Elrifi, CEO of Tiziana. Read full story HERE…